Deval A Lashkari

Bio

Deval has worked in the life sciences area since 1988 developing and commercializing novel technologies. He gained corporate and business development experience through senior management positions in a number of biotechnology companies. In addition, he was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he was Director of Product Development. He also worked with Operon Technologies, acquired by Qiagen, and Genometrix. D eval has represented THP on the boards of AcroMetrix (acquired by Life Technologies), Althea Technologies, AltheaDx, Applied Precision, Aurora Discovery (acquired by NEXUS), NEXUS Biosystems, SwitchGear Genomics and RareCyte. Deval received a BA from the University of California, Berkeley and a Ph.D. from Stanford University.